We provide evidence that increases in APO-TCN2 likely reflect a systemic and local inflammatory myeloid response which drives proliferation and intratumoral infiltration of B lymphocytes for improved anti-tumor immunity in these patients. The gene discussed is TCN2; the disease is neoplasm.